Richard Johnson - Phibro Animal Interim Officer
| PAHC Stock | USD 21.90 0.09 0.41% |
Executive
Mr. Richard G. Johnson is Chief Financial Officer of the company. He joined us in September 2002 and has served as Chief Financial Officer since then. Prior to joining us, Mr. Johnson served as Director of Financial Management for Laserdyne Prima, Inc., a manufacturer of laser cutting and welding systems, from 2001 to 2002 and as Vice PresidentPlanning and Control, Latin America for Ecolab, Inc., a global provider of cleaning and sanitation products, systems and services, from 1992 to 1999. Mr. Johnson served in various senior financial positions at Ecolab over a fifteen year period. He was employed by Coopers Lybrand from 1977 to 1985, in positions of increasing responsibility in the auditing practice. since 2002.
| Age | 75 |
| Tenure | 23 years |
| Address | Glenpointe Centre East, Teaneck, NJ, United States, 07666-6712 |
| Phone | 201 329 7300 |
| Web | https://www.pahc.com |
Phibro Animal Management Efficiency
The company has return on total asset (ROA) of 0.056 % which means that it generated a profit of $0.056 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0746 %, meaning that it created $0.0746 on every $100 dollars invested by stockholders. Phibro Animal's management efficiency ratios could be used to measure how well Phibro Animal manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.14, whereas Return On Tangible Assets are forecasted to decline to 0. At present, Phibro Animal's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 210.4 M, whereas Total Assets are forecasted to decline to about 568.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sauri Gudlavalleti | Dr Reddys Laboratories | 42 | |
| MD FAAFP | Collegium Pharmaceutical | 63 | |
| Vivek Mittal | Dr Reddys Laboratories | N/A | |
| Daniel Bernal | Procaps Group SA | N/A | |
| Bhethanabottla Phanimitra | Dr Reddys Laboratories | N/A | |
| Mary Fritz | Prestige Brand Holdings | N/A | |
| Jose Vieira | Procaps Group SA | 58 | |
| Sumera Hasham | Dr Reddys Laboratories | N/A | |
| Mannam Venkatanarasimham | Dr Reddys Laboratories | N/A | |
| Krista Davis | ANI Pharmaceuticals | 51 | |
| DO Ellis | Pacira BioSciences, | 53 | |
| Christopher Mutz | ANI Pharmaceuticals | 54 | |
| Dean Patras | Collegium Pharmaceutical | N/A | |
| Richard Kahr | Pacira BioSciences, | N/A | |
| Shawn Cross | Pacira BioSciences, | 57 | |
| Max Reinhardt | Pacira BioSciences, | 53 | |
| Archana Bhaskar | Dr Reddys Laboratories | 53 | |
| Deepak Sapra | Dr Reddys Laboratories | 45 | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| JD Esq | Pacira BioSciences, | 51 | |
| Thomas Rowland | ANI Pharmaceuticals | 58 | |
Management Performance
| Return On Equity | 0.0746 | ||||
| Return On Asset | 0.056 |
Phibro Animal Health Leadership Team
Elected by the shareholders, the Phibro Animal's board of directors comprises two types of representatives: Phibro Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phibro. The board's role is to monitor Phibro Animal's management team and ensure that shareholders' interests are well served. Phibro Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phibro Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ramon Fuenmayor, President Region | ||
| Daniel JD, Executive Director | ||
| Larry Miller, Chief Officer | ||
| Thomas Dagger, Senior Vice President General Counsel, Corporate Secretary | ||
| Jonathan Bendheim, Director and President MACIE Region and General Manager of Israel Operations | ||
| Damian Finio, Chief Officer | ||
| Mona Desai, VP Controller | ||
| Jean Filippi, Pres Region | ||
| Richard Johnson, Interim Officer | ||
| Glenn David, Chief Officer | ||
| Rob Aukerman, President Region | ||
| Anthony CPA, VP Treasurer | ||
| Jack Bendheim, Chairman of the Board and Presidentident, CEO | ||
| Daniel Bendheim, Executive Vice President Director, Corporate Strategy | ||
| Judith Weinstein, General VP | ||
| Michael Giambalvo, President Group | ||
| Lisa Escudero, Senior Vice President-Human Resources | ||
| Samson Li, President Region |
Phibro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phibro Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0746 | ||||
| Return On Asset | 0.056 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 1.61 B | ||||
| Shares Outstanding | 20.34 M | ||||
| Shares Owned By Insiders | 0.59 % | ||||
| Shares Owned By Institutions | 99.41 % | ||||
| Number Of Shares Shorted | 870.53 K | ||||
| Price To Earning | 11.39 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phibro Animal Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phibro Animal. If investors know Phibro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phibro Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.621 | Dividend Share 0.48 | Revenue Per Share | Quarterly Revenue Growth 0.237 | Return On Assets |
The market value of Phibro Animal Health is measured differently than its book value, which is the value of Phibro that is recorded on the company's balance sheet. Investors also form their own opinion of Phibro Animal's value that differs from its market value or its book value, called intrinsic value, which is Phibro Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phibro Animal's market value can be influenced by many factors that don't directly affect Phibro Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phibro Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Phibro Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phibro Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.